Genome British Columbia
VC Fund
Vancouver, Canada
Genome British Columbia is a VC fund in Vancouver focused on Health Care and Biotechnology. Genome BC, a non-profit research organization, leads genomics innovation on Canada’s West Coast and facilitates the integration of genomics into society. Their major investors are the Province of British Columbia and the Government of Canada through Genome Canada and Western Economic Diversification Canada. This funding is complemented bypartnerships with many national and international public and private funding organizations to drive BC’s bioeconomy.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Genome British Columbia invests in
Stages Genome British Columbia invests in
Countries Genome British Columbia invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$4.7M
- Venture - Series Unknown
- $370k–$586k
Investment Focus
Industry
- Health Care 9 (56%)
- Biotechnology 6 (38%)
- Medical 3 (19%)
- Medical Device 3 (19%)
- Therapeutics 2 (13%)
Stage
- Seed 8 (50%)
- Grant 3 (19%)
- Venture - Series Unknown 3 (19%)
- Series A 1 (6%)
- Series B 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tony Brooks
CFO& VP Entrepreneurship & Commercialization
|
CFO& VP Entrepreneurship & Commercialization | Total investments: 3 | Find email | |
Catalina Lopez-Correa
Chief Scientific Officer & Vice President Sectors
|
Chief Scientific Officer & Vice President Sectors | Total investments: 0 | Find email | |
Federica Di Palma
Chief Scientific Officer and Vice President Sectors
|
Chief Scientific Officer and Vice President Sectors | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BugSeq is leveraging advanced sequencing technologies to revolutionize infectious disease testing and pathogen surveillance. BugSeq’s analysis suite delivers unparalleled data analytics and industry-leading expertise to convert sequencing data into actionable results. By profiling tens of thousands of microorganisms and markers of antimicrobialresistance from any specimen, BugSeq enables broad adoption of sequencing to improve health. | Grant / Jul 08, 2026 | ||
| CereCura Nanotherapeutics is developing novel RNA therapeutics for central nervous system disorders. | Grant / Aug 06, 2025 | ||
| Verdi is building the data science platform for hyper-specific farm actions, starting with irrigation. | $4.7M / Seed / May 15, 2025 | ||
| Verdi Expeditions is a scalable platform for agricultural automation and tailored plant health. | $4.7M / Seed / May 15, 2025 | ||
| Every hospital in the world is faced with a major challenge - the rising cost of heathcare - we want to do something about it. Arbutus Medical’s purpose is to develop a portfolio of “frugal innovation” devices that save costs for hospitals and improve access to orthopedic surgery for 5 million patients by 2030. Arbutus Medical's flagshipproduct is a radically affordable orthopaedic power tool system that is used in North American Trauma Centers, veterinary hospitals, military deployments, NGO missions, and hospitals in over 30 low- and middle-income countries worldwide. | $2.3M / Seed / Feb 13, 2023 | ||
| Avivo Biomedical operates as a preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. | $250K / Grant / Mar 31, 2022 | ||
| LightIntegra Technology is a privately funded medical diagnostics company and launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer. LightIntegra strives to minimize platelet refractoriness. To this end, LightIntegra created ThromboLUX, a rapid in-vitro test that provides sizedistribution information for microparticles in blood products. As a routine test for platelet concentrates, ThromboLUX may identify which platelet units would be best suited for prophylaxis and which units are better suited for therapeutic use. Her years of research on platelet function led to a breakthrough discovery using dynamic light scattering to characterize platelets. Dr. Maurer recognized the opportunity to use this breakthrough - coupled with advances in laser and optics technology – to address a market need to provide a safe, quick and simple diagnostic test for microparticles, platelet quality and function. | $370.1K / Venture - Series Unknown / Jun 02, 2020 | ||
| Sonic Incytes is a medical device start-up company developing quantitative ultrasound for point-of-care diagnostic and procedure guidance. our mission to enable routine assessment and management of liver health, with diagnostic accuracy you can count on. | $2.5M / Seed / May 28, 2020 | ||
| BarrelWise Technologies creates technology to improve wine production and analysis, with products used by wineries in British Columbia, California, and Washington. The FS1 System, the company's flagship product, enables wineries to bring routine free SO2 checks to the cellar, reducing the process from days to minutes while maintaininglab-level accuracy. | Seed / Apr 16, 2020 | ||
| Acuva Technologies is developing ultraviolet light emitting diode (UV-LED) based drinking water purification systems targeting low to moderate volumes of water in various sizes. Acuva’s reactor is a compact, modular, and scalable system comprising UV LEDs, to provide a dose of UV radiation to water flowing through the device. The UV puriicationsystem obtains germicidal destruction of biological contaminants such as viruses and bacteria. | $1M / Series B / Sep 30, 2019 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Genome British Columbia invest in?
Genome British Columbia invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Grant stage. Most of the 16 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Genome British Columbia's check size?
Genome British Columbia typically joins rounds of $1M–$4.7M at Seed and $370k–$586k at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Genome British Columbia participates in.
How do I contact Genome British Columbia?
Public channels for Genome British Columbia include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Genome British Columbia?
The team at Genome British Columbia includes Tony Brooks (CFO& VP Entrepreneurship & Commercialization), Catalina Lopez-Correa (Chief Scientific Officer & Vice President Sectors) and Federica Di Palma (Chief Scientific Officer and Vice President Sectors). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
